Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.

Por Hug, V., Kau, S., Hortobagyi, G. N., Jones, L.
Publicado em 1991

Survival differences among women with de novo stage IV and relapsed breast cancer

Por Dawood, S., Broglio, K., Ensor, J., Hortobagyi, G. N., Giordano, S. H.
Publicado em 2010

Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects

Por Pemmaraju, N., Munsell, M. F., Hortobagyi, G. N., Giordano, S. H.
Publicado em 2012

Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients

Por Jiralerspong, S., Kim, E. S., Dong, W., Feng, L., Hortobagyi, G. N., Giordano, S. H.
Publicado em 2013

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

Por Smith, B L, Chin, D, Maltzman, W, Crosby, K, Hortobagyi, G N, Bacus, S S
Publicado em 2004

Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria

Por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Hortobagyi, G N, Ueno, N T
Publicado em 2010

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer

Por He, X., Esteva, F. J., Ensor, J., Hortobagyi, G. N., Lee, M.-H., Yeung, S.-C. J.
Publicado em 2012

Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity.

Por Broadwater, J R, Edwards, M J, Kuglen, C, Hortobagyi, G N, Ames, F C, Balch, C M
Publicado em 1991

PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin

Por Lee, J, Bartholomeusz, C, Krishnamurthy, S, Liu, P, Saso, H, LaFortune, T A, Hortobagyi, G N, Ueno, N T
Publicado em 2012

Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers

Por Mazouni, C, Arun, B, André, F, Ayers, M, Krishnamurthy, S, Wang, B, Hortobagyi, G N, Buzdar, A U, Pusztai, L
Publicado em 2008

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity

Por Reddy, S M, Barcenas, C H, Sinha, A K, Hsu, L, Moulder, S L, Tripathy, D, Hortobagyi, G N, Valero, V
Publicado no Br J Cancer (2018)

Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer

Por Chavez-MacGregor, M., Zhao, H., Kroll, M., Fang, S., Zhang, N., Hortobagyi, G. N., Buchholz, T. A., Shih, Y.-C., Giordano, S. H.
Publicado em 2011

Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy

Por Sohn, J., Do, K. A., Liu, S., Chen, H., Mills, G. B., Hortobagyi, G. N., Meric-Bernstam, F., Gonzalez-Angulo, A. M.
Publicado em 2013

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

Por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Berry, D A, Islam, R, Theriault, R L, Hortobagyi, G N, Ueno, N T
Publicado em 2010

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

Por Delpech, Y, Coutant, C, Hsu, L, Barranger, E, Iwamoto, T, Barcenas, C H, Hortobagyi, G N, Rouzier, R, Esteva, F J, Pusztai, L
Publicado em 2013

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Por Rugo, H. S., Hortobagyi, G. N., Yao, J., Pavel, M., Ravaud, A., Franz, D., Ringeisen, F., Gallo, J., Rouyrre, N., Anak, O., Motzer, R.
Publicado no Ann Oncol (2016)

Survival among women with triple receptor-negative breast cancer and brain metastases

Por Dawood, S., Broglio, K., Esteva, F. J., Yang, W., Kau, S.-W., Islam, R., Albarracin, C., Yu, T. K., Green, M., Hortobagyi, G. N., Gonzalez-Angulo, A. M.
Publicado em 2009

Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy

Por Gonzalez-Angulo, A. M., Liu, S., Chen, H., Chavez-MacGregor, M., Sahin, A., Hortobagyi, G. N., Mills, G. B., Do, K.-A., Meric-Bernstam, F.
Publicado em 2013

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy

Por Gonzalez-Angulo, A M, Parinyanitikul, N, Lei, X, Mittendorf, E A, Zhang, H, Valero, V, Hunt, K K, Hortobagyi, G N, Chavez-MacGregor, M
Publicado no Br J Cancer (2015)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

Por Cheng, Y C, Valero, V, Davis, M L, Green, M C, Gonzalez-Angulo, A M, Theriault, R L, Murray, J L, Hortobagyi, G N, Ueno, N T
Publicado em 2010